These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23284776)

  • 21. Insulin glargine and risk of cancer: a meta-analysis.
    Du X; Zhang R; Xue Y; Li D; Cai J; Zhou S; Huang Z; Yu R; Liu Y
    Int J Biol Markers; 2012 Oct; 27(3):e241-6. PubMed ID: 22865296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
    Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
    Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
    Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
    Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
    Sorli C; Warren M; Oyer D; Mersebach H; Johansen T; Gough SC
    Drugs Aging; 2013 Dec; 30(12):1009-18. PubMed ID: 24170235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of breast cancer by individual insulin use: an international multicenter study.
    Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
    Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
    DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
    Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review.
    Caires de Souza AL; de Assis Acurcio F; Guerra Júnior AA; Rezende Macedo do Nascimento RC; Godman B; Diniz LM
    Appl Health Econ Health Policy; 2014 Feb; 12(1):19-32. PubMed ID: 24385261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma.
    Besic N; Satej N
    BMC Res Notes; 2013 Oct; 6():416. PubMed ID: 24131755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
    JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Insulin Icodec Versus Glargine U100: A Meta-Analysis of Randomized Controlled Trials.
    Zerihun K; Mhanna M; Ayesh H; Ghazaleh S; Khader Y; Beran A; Aldhafeeri A; Sharma S; Iqbal A; Legesse H; Jaume J
    Am J Ther; 2023 Sep-Oct 01; 30(5):e480-e483. PubMed ID: 37713703
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and safety of insulin detemir versus glargine in patients with diabetes: a systematic review and meta-analysis.
    Rezaei S; Taheri A; Taheri S; Kasirzadeh S; Fatemi B; Sorato MM
    Expert Rev Clin Pharmacol; 2022 Jun; 15(6):767-777. PubMed ID: 35579011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
    Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
    N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Insulin Icodec Versus Glargine U100: A Meta-Analysis of Randomized Controlled Trials: Erratum.
    Am J Ther; 2024 Mar-Apr 01; 31(2):e207. PubMed ID: 38518276
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
    Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
    JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
    Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
    J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials.
    Sun D; Zhang X; Hou XX
    Diabetes Technol Ther; 2018 Sep; 20(9):622-627. PubMed ID: 30095984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.
    Karlstad O; Starup-Linde J; Vestergaard P; Hjellvik V; Bazelier MT; Schmidt MK; Andersen M; Auvinen A; Haukka J; Furu K; de Vries F; De Bruin ML
    Curr Drug Saf; 2013 Nov; 8(5):333-48. PubMed ID: 24215311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
    Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
    Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.